The Influence of Glycemic Control on Heart Rate Variability and Blood Pressure in Adult Patients with the Type 1 Diabetes by Pertseva, N.O. et al.
  
 26, L. Pasteur str., Dnipro, 49038, Ukraine. Telephone: +38 (050) 971 94 88 
corresponding author e-mail: n.pertseva17@gmail.com 
 
THE INFLUENCE OF GLYCEMIC CONTROL ON HEART 
RATE VARIABILITY AND BLOOD PRESSURE IN 
ADULT PATIENTS WITH THE TYPE 1 DIABETES 
Nataliia Pertseva
 , Iryna Tyshchenko, Kateryna Moshenets 
Department of Endocrinology, SE “Dnipropetrovsk Medical Academy 
of Heath Ministry of Ukraine”, Dnipro, Ukraine 
received: November 15, 2017 accepted: February 06, 2018 
available online: March 15, 2018 
Abstract 
Background and aims: to identify heart rate variability (HRV) and blood pressure (BP) 
in patients with type 1 diabetes depending on the duration of disease and glycemic 
control. Materials and methods: 43 patients were examined. All patients were divided 
into 2 groups according to the level of НвА1с: group 1 (n=21) with НвА1с ≤ 7.5% and 
group 2 (n=22) with НвА1с > of 7.5%. All patients underwent daily monitoring of 
electrocardiogram Holter and ambulatory BP monitoring within 24 hours in parallel with 
long term monitoring of blood glucose. Results: Hyppoglycemia is characterized by 
significant decrease root mean square difference between adjacent RR intervals (RMSSD) 
(r = - 0.531; p = 0.003) and number of consecutive RR intervals, the difference between 
them is more than 50 ms expressed as a percentage of total number of RR-intervals 
(pNN50%) (r = the - 0.503; p = 0.005) and increase of Low Frequency/High Frequency 
Ratio (LF/HF) (r = 0552; p = 0.002). Patients with hypoglycemia had significantly 
higher daily diastolic pressure area index (DPAI24) (p = 0.016), and daily diastolic 
pressure time index DPTI24 (p = 0.025). Conclusion: our findings demonstrate the need 
to reduce the frequency of hypoglycemia episodes in patients with T1DM. 
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Background and aims 
According to International Diabetes 
Federation (IDF) 415 million adult people suffer 
from diabetes mellitus (DM) in the world. The 
number of cases will reach 642 million people 
by 2040 with preserving actual trends. Type 1 
diabetes mellitus (Type 1 DM) will raise from 
7% to 17%. Although Type 1 DM is less 
common than Type 2 DM, the annual growth is 
approximately 3% in the world [1]. 
Type 1 DM leads to disability in young and 
middle age, due to progression of its 
complications (mainly nephropathy and 
amputations) [2-4]. Evolving metabolic changes 
contribute to the development of cardiovascular 
complications in the patients’ employable 
category that is results both in medical and social 
problems. Mortality from cardiovascular disease 
in patients with diabetes is 2-3 times higher than 
among others [4-6]. 
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The clinical manifestations of the 
cardiovascular system involvement in Type 1 
DM include resting tachycardia, accompanied by 
lengthening of the QT interval, the fixed heart 
rate (syndrome denervation of the heart), and 
reduced tolerance to physical activity. Also, 
orthostatic hypotension, and painless myocardial 
ischaemia are included according to the 
recommendations of the American Diabetes 
Association (ADA) [7]. 
Lengthened QT interval leads to increased 
risk of arrhythmias [8,9]. Ventricular 
arrhythmias are especially dangerous. They can 
lead to sudden death due to acute heart failure – 
the so-called "dead-in-bed" syndrome [10,11]. 
Firstly, the clinical value of analysis of heart rate 
variability (HRV) was revealed in the early 60`. 
Under physiological conditions, regulation of 
heart rhythm is the result of automatic cells’ 
rhythmic activity in the sinus node, which 
modulates the influence of the autonomic and 
central nervous systems, humoral and reflex 
effects. The decrease of HRV is regarded as a 
powerful predictor of sudden cardiac death in 
patients with cardiovascular disease, as well as 
among others. In addition, the decrease of HRV 
is closely associated with the deterioration of the 
functional state of the cardiovascular system 
[12]. Technologies were standardized and 
recommendations for practical use of HRV 
indexes were developed by the working group of 
the European society of cardiology and the 
North American society of pacing and 
electrophysiology in 1996 [13,14]. 
Nowadays, the unsolved problem of 
occurrence of hypoglycemic conditions in 
patients with type 1 diabetes remains. They exert 
influence on pro-arrhythmogenic action and 
accelerate the development of both micro - and 
macrovascular complications of diabetes, despite 
the new types of insulin. 
The aim of the investigation was to reveal 
changes of heart’s rate variability and blood 
pressure in patients with type 1 diabetes 
depending on disease’s duration and glycemic 
control. 
Materials and methods: 
Fourty-three patients with DM (males-23 
(53%), females - 20 (47%) were examined in the 
Endocrinology Department of University Clinic 
of «Dnepropetrovsk Medical Academy» between 
October 2016 and September 2017. 
The diagnosis of diabetes mellitus type 1 
was made according to American Diabetes 
Association criteria - 2017.  
The inclusion criteria were: males and 
females with type 1 diabetes, from 18 to 40 years 
old without arterial hypertension. 
The exclusion criteria were: type 2 diabetes; 
diabetic ketoacidosis at the time of inclusion; 
secondary DM; body mass index (BMI) > 40 
kg/m2; diabetic proliferative retinopathy; 
chronic kidney diesease IIIB - V; diabetic foot 
(class II according to Wagner and above); heart 
failure III / IV by the New York Heart 
Association (NYHA); congenital and acquired 
heart disease; acute coronary syndrome, acute 
ischemic stroke and transient ischemic attack; 
exacerbation of accompanying chronic diseases; 
acute physical illness; myocarditis in past 
history; cancer up to 5 years from the full course 
of therapy; antiretroviral therapy; diagnosed 
viral hepatitis B and C; pregnancy. 
All patients had signed the voluntary 
informed consent, approved by the local Ethics 
Committee before their inclusion in the study. 
All patients were treated on the basal-bolus 
insulinotherapy, the daily dose of insulin was 44 
± 3,15 IU. The C-peptide, HbA1c, blood 
creatinine, the first morning urinary albumin 
excretion (UAE) were determined for 
verification and evaluation of control. C-peptide 
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was determined on an electrochemiluminescence 
automatic immunochemical analyzer COBAS e 
411, Roche Diagnostics GmbH & Hitachi, 
Japan, 2012. The concentration of blood 
creatinine, HbA1c and microalbumin were 
determined using automatic biochemical 
analyzer SAPPHIRE 400, TokioBoeki, Japan, 
2009. GFR was calculated according to the 
formula CKD-EPI [15]. 
Long-term monitoring of blood glucose 
levels was conducted by using the system 
CGMS (Continuous Glucose Monitoring 
System, Medtronic MiniMed, USA). 
This system detects electrical signals every 
10 seconds and transforming them in glucose 
values every 5 minutes. The boundaries of the 
measurement of glucose levels by this method 
range from 2.2 mmol/l to 22.2 mmol/l [16]. The 
patients performed at least four blood glucose 
measurements per day using the individual 
glucose test for the calibration data of the sensor 
with capillary blood. Hypoglycemia was 
considered as an episode of lower blood glucose 
level less than 3.9 mmol/l according to the 
criteria of ADA [7]. 
The daily monitoring of the 
electrocardiogram (ECG) Holter and extended 
monitoring of blood pressure (BP) within 24 
hours on the unit DigiTrak XT (Philips Medical 
Systems, USA) were carried out in the free 
moving regime. It was made in parallel with 
long term monitoring of blood glucose. The 
temporal and spectral HRV parameters were 
examined, which were computed using the 
software ARNIKA, version 8.3.9. 
Analysis of the time domain was carried out 
using these indicators: 
SDNN (ms) – the standard deviation of 
normal intervals RR (NN), which represents the 
total effect of vegetative regulation of the heart. 
RMSSD (ms) – the root mean square 
difference between adjacent RR intervals. It 
reflects the activity of parasympathetic link of 
vegetative regulation. 
PNN50 (%) - number of consecutive RR 
intervals, the difference between them is more 
than 50 ms expressed as a percentage of the total 
number of RR-intervals, reflecting the degree of 
predominance of parasympathetic link of 
regulation over the sympathetic (relative value). 
The circadian profile was assessed by the 
circadian index (CI), which was calculated as the 
ratio of the average daily to the average night 
heart rate (HR). 
Spectral analysis of HRV was calculated 
using the algorithm of fast Fourier transform 
according to the recommendations of the 
American College of Cardiology and American 
Heart Association [13]. The power of the four 
main frequency bands was estimated: high 
frequency (HF) - 0.15-0.40 Hz, low freguency 
(LF) - 0.04-0.15 Hz, very low frequency (very 
low frequency - VLF) - 0.0033-0.04 Hz, as well 
as total power of the spectrum (TP), the ratio of 
low frequency components to high frequency 
(LF / HF) was calculated. 
During the day time measuring intervals of 
BP were 15 minutes, and at night – 30 min. one 
time per hour (according to the 
recommendations of the Scientific Committee in 
the field one day monitoring of BP (DMBP) 
1990). According to DMBP the average systolic 
blood pressure (SBP), mean diastolic blood 
pressure (DBP), the average level of pulse 
pressure (PBP) were calculated. These indicators 
were calculated per day, as well as for the period 
of sleep and wakefulness. The circadian profile 
of BP was evaluated by calculating the daily 
index of SBP and DBP, as well as the magnitude 
and rate morning blood pressure increase. 
Echocardiography examination was carried 
out for studying of cardiac hemodynamics and 
determining the contractility of the myocardium 
to exclude organic pathology. Standard methods 
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were used on the apparatus "PHILLIPS HD3". 
Aorta, left atrium, right atrium, interventricular 
septum, and posterior wall thickness, left 
ventricle in systole and diastole, and the right 
ventricle were evaluated. Left ventricular 
ejection fraction was determined. Reference 
values for were provided by the American 
Society of Echocardiography in conjunction with 
the European Association of Cardiovascular 
Imaging [17].  
Statistical analysis 
The statistical analysis was conducted using 
the licensed software package "Statistica 6.1" 
(StatSoftInc). Comparison between groups was 
carried out by the independent t-test (for 
parametric data) or the test of Mann-Whitney 
(nonparametric test). Data with Gaussian 
distribution were expressed as mean and 
standard deviation (M±SD). The data were 
described by median and quarterly ranges (Me 
(25%; 75%) when their normal distribution was 
not validated. the Chi
2
 test for the comparison 
between two percentages and the analysis of 
variance for the comparison between several 
means. Differences were considered statistically 
significant at p < 0.05. 
Results 
Average age of patients - 27,6 ± 2,49 years, 
disease duration  - 10,8 ± 1,46 years, BMI 22,6 ± 
0,62 kg / m
2
 
Patients were divided into 2 groups 
according to the level НвА1с: group 1 (n=21) 
with НвА1с ≤ 7,5 % and group 2 (n=22) with 
НвА1с > 7,5 %.  
Table 1. General characteristics of patients’ groups. 
Indicator Group 1 
n=21 
Group 2 
n=22 
P value 
Age,years 31.6±2.01 31.5±1.88 0.994 
Duration DM 1 
type, years  
6.3±2.34 12.4±2.21 0.123 
BMI kg/m2 23.0±1.16 22.5±2.21 0.716 
HbA1c, % 6.65 (6.5; 
6.91) 
9.6 (8.8; 
11.0)* 
0.000 
Minimal blood 
glucose, mmol/l 
3.96 (2.2; 
4.8) 
4.71 (2.2; 
6.3) 
0.343 
Maximal blood 
glucose, mmol/l 
12.61 (7.5; 
13.9) 
16.54 (9.8; 
18.7) 
0.023* 
Average  blood 
glucose, mmol/l 
8.37 (6.8; 
9.24) 
10.72 (8.5; 
12.6) 
0.017* 
Waist 
circumference / 
thigh 
0.80 (0.69; 
0.88) 
0,81 (0.76; 
0.85) 
0.694 
C-peptide, ng/ml 0.41 (0.01; 
0.57) 
0,02 (0.01; 
0.11)* 
0.018 
The daily dose of 
insulin, unit 
36.0±5.22 40.5±10.75* 0.015 
Hypoglycemia % 42.9 49.5 0.904 
Albuminuria 
mg/l 
22.8 (21.6; 
38.9) 
37,3 (25.0; 
53.8)* 
0.035 
GFR (CKD-EPI) 
ml/min/1,73m2  
84.6±3.30 81.1±3.52 0.760 
Average SBP 
mm/mercury 
column 
113.2±4.71 115.2±2.13 0.834 
Average DBP 
mm/mercury 
column 
68.3±3.40 71.0±31.44 0.851 
Average PBP 
mm/mercury 
column 
42.9±2.14 45.0±1.22 0.675 
Note: * p <0.05, comparing group 2 with group 1 
Table 2. Characteristics of HRV in patients’ groups   
Indicator Group 1 
n=21 
Group 2 
n=22 
P value 
SDNN ms  
cir.period 
107.0 (101.5 
; 122.0) 
114.5 (90.5; 
123.5) 
0.140 
RMSSD ms 
cir.period 
25.0 (23.0; 
42.0) 
29.0 (25,0; 
42.0) 
0.103 
pNN50%  cir. 
period 
5.0 (4.0; 
18.0) 
7.5 (5.0; 
12.0) 
0.109 
TP ms
2
 cir. 
period  
9075.0 
(6754.0; 
12488.0) 
7493.5 
(4527.0; 
10717.0) 
0.236 
VLFms
2
 
cir.period 
6576.0 
(4743.,0; 
7873.0) 
4640.5 
(3015.0; 
6320.0) 
0.539 
LF ms
2
 cir. 
period 
 
2167.0 
(1669.0; 
3357.0) 
2138.0 
(1192.0; 
3544.0) 
0.125 
HFms
2
 cir. 
period 
381.0 (320.0; 
1122.0) 
627,0 (324.0; 
1077.0) 
0.147 
LF/HF cir. 
period 
4.5 (3.1; 6.7) 4,1 (3.3; 4.9) 0.203 
 
There were no statistical differences 
between groups in age, duration of disease, the 
basic anthropometric indexes, daily dose of 
insulin, the level of daily BP, the GFR level, and 
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did not differ by the frequency of hypoglycemia, 
(Table 1), as well as on spectral and temporal 
characteristics of HRV (Table 2). 
The correlation analysis for the duration of 
Type 1 DM revealed increasing LF / HF 
(r=0.383; p=0.045), increasing SBP at night 
(r=0.372; p=0.039) and for 24 hours (r=0.386; 
p=0.046). Indicators of DBP to the greater extent 
changed the course of the disease. The direct 
positive correlation between the duration of 
Type 1 DM and the increase in the average DBP 
for 24 hours (r=0.446; p=0.025), mean DBP 
during the day (r=0.396; p=0.021), mean DBP at 
night (r=0.537; p=0.020) were revealed, too 
(Figure 1). Also, this positive correlation was 
revealed in increasing of daily performance of 
the diastolic pressure area index (DPAI24) 
(r=0.422; p=0.028), area index of night DBP 
(r=0.414; p=0.032), and daily performance of the 
diastolic pressure time index (DPTI24) (r=0.411; 
p=0.033), time index of night DBP (r=0.428; 
p=0.026). 
 
Figure 1. Dynamics of indicators of DPAI24 and DPTI24 with increasing duration of type 1 diabetes. 
Additionally, the increase in the duration of 
the disease was accompanied by deterioration in 
glycemic control, assessed by HbA1c level 
(r=0.381; p=0.046). 
The presence of hypoglycemic episodes 
affected both on the temporal and spectral HRV 
indices, irrespective of the level of HbA1c 
(Table 3). The frequency of hypoglycemic 
episodes increased with increasing duration of 
Type 1 DM (r=0.4; p=0.026). 
Table 3. Correlation of HRV parameters, 
depending on hypoglycemia 
Indicator Spearman R P value 
SDNN ms  circadian 
period 
-0.339 0.144 
SDNN ms  night -0.352 0.061 
RMSSD ms circadian -0.531* 0.003 
period 
RMSSD ms  day -0.373* 0.046 
RMSSD ms  night -0.506* 0.005 
pNN50%   circadian 
period 
-0.503* 0.005 
pNN50%  day -0.316* 0.094 
pNN50%   night -0.515* 0.004 
TP  ms
2
  night -0.390* 0.017 
LF  ms
2
  night -0.406* 0.029 
HF  ms
2
 circadian 
period 
-0.489* 0.007 
HF ms
2
  day -0.323* 0.087 
HF  ms
2
  night -0.506* 0.005 
LF/HF  circadian 
period 
0.552* 0.002 
LF/HF  day 0.328* 0.003 
LF/HF  night 0.522* 0.004 
Notice : * р <0,05. 
 
The groups were divided into subgroups 
according to the absence (A) or presence (B) of 
hypoglycemia (Table 4). 
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Table 4. Characteristics of patients’ subgroups. 
Indicator Group 1А 
n=10 
Group 1В 
n=11 
P value Group 2А 
n=10 
Group 2В 
n=12 
P value 
Duration DM 
1 type, years 
2.0±0.52 11.0±3.18* 0.04 9.3±2.26 15.8±4.24 0.144 
HbA1c, % 6.62 (6.8; 6.84) 6.61 (6.5; 6.91) 0.981 11.29 (9.1; 
10.7) 
11.31 (8.8; 11.0) 0.985 
C-peptide, 
ng/ml 
0.171±0.07 0.024±0.09 * 0.017 0.16±0.05 0.10±0.01 0.459 
Average  
blood glucose, 
mmol/l 
8.41 (6.8; 9.24) 8.29 (6.5; 9.22) 0.412 10.72 (8.9; 
12.2) 
10.13 (8.1; 13.4) 0.357 
The daily 
dose of 
insulin, unit 
29.5±5.17 44.7±9.34 0.116 49.5±10.21 43.0±8.54 0.394 
SDNN ms  
cir. period 
106.0 (102.5; 
122.5) 
114.0 (91.5; 
123.0) 
0.0267 112.5 (96.5; 
130.5) 
102.0 (77.0; 
118.0) 
0.167 
RMSSD ms  
cir. period 
24.0 (22.0; 41.0) 29,5 (25.5; 42.0)* 0.028 31.5 (28.0; 
43.0) 
23.5 (14.0; 
34.0)* 
0.015 
pNN50%  cir. 
period 
4.5 (4.0; 19.0) 7.0 (5.5; 12.5)* 0.032 8.5 (6.0; 
13.5) 
4,5 (1.0; 11.0)* 0.024 
TP ms
2
 cir. 
period 
11220.5 
(8356.5; 
12781.0) 
7305.0 
(4225.0; 9057.0) 
0.099 8032.0 
(6182.0; 
10345.0) 
6038.0 
(3890.0; 
11695.0) 
0.593 
LF  ms
2
 cir. 
period 
3015.5 
(2267.0; 3405.0) 
1705.0 
(1185.0; 2245.0) 
0.081 2459.5 
(1895.5; 
3604.4) 
1526.0 
(1030.0; 2930.0) 
0.492 
HF  ms
2
 cir. 
period 
1059.5 
(332.0; 2118.0) 
325.0 
(168.0; 830.5)* 
0.019 729.0 
(495.0; 
1153.0) 
380.0 
(149.0; 713.0)* 
0.045 
LF/HF cir. 
period 
3.10 
(2.10; 4.20) 
6.80 
(4.55; 6.90)* 
0.018 3.40 
(2.40; 4.30) 
4.35 
(4.10; 6.50)* 
0.013 
Average SBP 
mm/mercury 
column 
 
112.0±5.87 115.5±4.33 0.767 115.8±3.18 114.4±4.16 0.746 
Average DBP 
mm/mercury 
column 
67.3±6.25 70.2±7.82 0.716 71.8±10.12 70.1±7.04 0.562 
Average PBP 
mm/mercury 
column 
44.8±7.21 46±6.32 0.537 44.4±6.15 45.6±8.43 0.642 
SPAI24 0.1 (0; 10.35) 0.24 (0.8; 13.25) 0.254 0.15 (0; 
12.45) 
0.55 (0; 12.35) 0.324 
SPTI24 0.18 (0; 10.74) 0.26 (0.9; 14.57) 0.387 0.3 (0; 7.9) 1.70 (0.1; 11.9) 0.495 
DPAI24 4.3 (0;13.9) 11.5 (0; 13.1)* 0.012 5.20 (1.45; 
14.35) 
6.80 (3.30; 
10.6)* 
0.016 
DPTI24,% 4.4 (0;14.1) 15.5 (0;14.2)* 0.001 5.75 (2.35; 
12.85) 
6.40 (0.9; 15.4)* 0.025 
Note: * p <0.05, comparing subgroup B with group A within one group. 
 
There was a lower C - peptide mean level in 
group 1B – 0.024±0.09 vs group 1A – 
0.171±0.07 (p=0.017) that probably influenced 
the occurrence of hypoglycaemic episodes in the 
group with satisfactory control. 
Decreasing temporal indices of HRV was 
identified in group 2B compared to 2A: RMSSD 
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per day to 23.5 (14.0; 34.0) vs. 31.5 (28.0; 43.0) 
(p =0.015), pNN50% per day 4.50 (1.0, 11.0) vs 
8.50 (6,00; 13.50) (p =0.024) and daily 
frequency characteristics of HRV: HF 380.0 
(149.0; 713.0) against 729.0 (495.0; 1153.0) (p 
=0.045). The index LF / HF was significantly 
lower: 3.40 (2.40; 4.30) vs 4.35 (4.10; 6.50) 
(p=0.013) in group 2A (Figure 2). 
 
Figure 2. Indices of HRV in groups with different glycemic 
control depending on the presence of hypoglycemia. 
Among all BP monitoring parameters the 
DPAI24 and DPTI24 are the most validative for 
confirmation of hypoglycemic episodes. In our 
study was showed DPAI24 6.80,0 (3.30; 10.6) vs 
5.20 (1.45; 14.35) (p=0.016), and DPTI24 6.4 
(0.9; 15.4) as against 5.75 (2.35; 12.85) 
(p=0.025), compareing groups 2B and 2A. 
Comparable data were obtained in group 1: 
DPAI24 11.5 (0; 13.1) vs 4.3 (0;13.9) (p=0.012), 
and DPTI24 15.5 (0;14.2) as against 4.4 (0;14.1) 
(p=0.001), compareing groups 1B and 1A.  
Discussion 
We confirmed in our study results showed 
da Silva A.K. et al., 2017, found that patients 
with type 1 diabetes had a significant decrease in 
HRV time values, such as RMSSD, PNN50% 
[18]. In another study da Silva T.P. et al., 2017, 
studied the spectral analysis of HRV in patients 
with Type 1 DM. Patients with moderate and 
severe hypoglycemia were older, had a longer 
duration of diabetes, which correlated with the 
astonishment of chronic complications. The 
authors observed a lower HRV in the high-
frequency spectral analysis band, and an increase 
in the LF / HF index [19]. 
We showed that hypoglycemic conditions 
lead to further progression of autonomic 
dysfunction and even greater reduction of HRV, 
namely, RMSSD, pNN50%, and an increase in 
the LF / HF index. The increase of duration Type 
1 DM was accompanied by deterioration in 
glycemic control, assessed by HbA1c level (r = 
0.381; p = 0.046) and increased the frequency of 
hypoglycemia (r = 0.4; p =0.046). Similar results 
were obtained by Limberg J.K. et al. 2015, 
which showed that these rates decreased even 
more during episodes of hypoglycemia [20]. All 
this changes leads to cardiovascular death.  
Although the duration of disease leads to an 
increase in SBP (r=0.386; p=0.046) and DBP 
(r=0.446; p=0.025), but the growth of DPAI24 
and DPTI24 correlated with the presence of a 
hypoglycaemic episodes. 
Thus, hypoglycemia has negatively affects 
in cardiovascular functiob both by reducing the 
temporal and spectral parameters of HRV, and at 
the expense of increasing DBP, which in turn 
further reduces the autonomic cardiac activity. 
Conclusions 
The determination of RMSSD, pNN50%, 
LF, HF and LF / HF is the most reliable criteria 
for the evaluation of changes of heart rate 
variability in patients with Type 1 DM. 
The increase the duration of type 1 diabetes 
has the correlation with the decrease of HRV as 
by time and frequency indicators, namely, the 
decrease in RMSSD, pNN50% and the increase 
of LF/HF are observed. 
Hypoglycemia is the key factor leading to 
the decline in HRV indices, namely RMSSD, 
pNN50% and increased LF/HF. The incidence of 
hypoglycaemia episodes increases with duration 
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of type 1 diabetes, regardless of HbA1c 
indicator. 
The daily variability of BP in patients with 
type 1 diabetes is realized through the changes of 
DBP. The duration of the disease has the 
significant correlation with the increase in the 
average DBP during the day and in periods of 
sleep and wakefulness, increased DPAI24.  
All the above findings demonstrate the need 
to reduce the frequency of hypoglycaemic 
episodes in patients with T1DM, as its impact on 
HRV and BP, regardless of glycaemia control 
and duration of disease affects the functional 
state of the cardiovascular system in a negative 
mode. 
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